Lexaria Bioscience Corp. (LEXX)

Market Cap	48.70M
Revenue (ttm)	411,019
Net Income (ttm)	-4.85M
Shares Out	15.81M
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	46,933
Open	3.170
Previous Close	3.190
Day's Range	3.060 - 3.278
52-Week Range	0.850 - 6.850
Beta	1.02
Analysts	Strong Buy
Price Target	11.00 (+257.14%)
Earnings Date	Nov 18, 2024

About LEXX

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company’s DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 5
• Stock Exchange: NASDAQ
• Ticker Symbol: LEXX
• Website: https://lexariabioscience.com

Financial Performance

In 2023, Lexaria Bioscience's revenue was $226,208, a decrease of -11.43% compared to the previous year's $255,397. Losses were -$6.66 million, -8.31% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for LEXX stock is "Strong Buy." The 12-month stock price forecast is $11.0, which is an increase of 257.14% from the latest price.

Price Target

$11.0

(257.14% upside)

Analyst Consensus: Strong Buy